866-997-4948(US-Canada Toll Free)

Galvus (Type 2 Diabetes) Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Diabetes

No. of Pages : 42 Pages


GlobalDatas pharmaceuticals report, Galvus (Type 2 Diabetes) Analysis and Forecasts to 2020 provides Galvus sales estimates for EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2007-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Galvus including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Galvus including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2007-2020 for Galvus in EU5 and Japan

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Contents

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 5
2.1 Diabetes 5
2.2 Epidemiology 5
2.2.1 Prevalence 5
2.2.2 Mortality 7
2.3 Etiology and Risk Factors 9
2.3.1 Obesity 9
2.3.2 Sedentary Lifestyle 9
2.3.3 Family History and Genetics 9
2.3.4 Ethnicity 9
2.3.5 Old Age 9
2.4 Economic Impact of Diabetes 9
2.5 GlobalData Report Guidance 10

3 Type 2 Diabetes: Market Characterization 11
3.1 Type 2 Diabetes Market 11
3.2 Type 2 Diabetes Market Forecasts 12
3.3 Type 2 Diabetes Market: Drivers and Restraints 13
3.3.1 Drivers 13
3.3.2 Restraints 14

4 Classification of Diabetes 15
4.1 Types of Diabetes 15
4.1.1 Type 1 Diabetes 15
4.1.2 Type 2 Diabetes 15
4.1.3 Gestational Diabetes 15
4.2 Diabetes Complications 15
4.2.1 Cardiovascular Disease 15
4.2.2 Nephropathy 16
4.2.3 Neuropathy 16
4.2.4 Amputation 16
4.2.5 Retinopathy 16

5 Evolution of Anti-Diabetic Treatments 17

6 Medications 18

6.1 Insulin 18
6.2 Oral Medications 18
6.2.1 Sulfonylureas (SUR) 18
6.2.2 Biguanides (BGDs) 18
6.2.3 Alpha-Glucosidase Inhibitors (AGI) 20
6.2.4 Meglitinides 20
6.2.5 Thiazolidinediones (TZDs) 21
6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors 22
6.2.7 Oral Combination Therapy 22
6.3 Other Injectionable Medications 23
6.3.1 Pramlintide 23
6.3.2 Exenatide 23
6.4 Market Share as per Classes in Type 2 Diabetes 23

7 Galvus 24
7.1 Introduction 24
7.2 Mechanism of Action 24
7.3 Clinical Studies 25
7.3.1 Monotherapy Trials 25
7.3.2 Combination Therapy Trials 26
7.3.3 GALIANT study 26
7.4 Approval History of Galvus 27
7.5 Factors Affecting Sales of Galvus 27
7.5.1 Potential Benefits 27
7.5.2 Approval of Eucreas 27
7.5.3 Blackbox Warnings 27
7.5.4 Approved only as Dual Therapy 27
7.5.5 Change in Labeling of Galvus 27
7.5.6 Approval in US 28
7.5.7 Increasing Competition 28
7.6 Drug Evaluation 28
7.6.1 Drug Risk Benefit Score 28
7.6.2 Intensity of Competition 29
7.7 Sales Estimates 29
7.7.1 Target Patient Pool for Galvus 29
7.7.2 Dosing 29
7.7.3 Market Penetration 29
7.7.4 Annual Cost of Therapy 30
7.7.5 Sales Estimates of Galvus 31

8 Type 2 Diabetes Market: Appendix 39
8.1 Market Definitions 39
8.2 List of Abberiviations 39
8.3 Research Methodology 39
8.3.1 Coverage 40
8.3.2 Secondary Research 40
8.3.3 Forecasting 40
8.3.4 Net Penetration of Drug 41
8.3.5 Net Annual Dosing 41
8.3.6 Annual Cost of Therapy 41
8.3.7 Primary Research 41
8.3.8 Expert Panels 41
8.4 Drug Sales Estimates Model 42
8.5 Contact Us 42
8.6 Disclaimer 42
8.7 Sources 42

List of Table


Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 5
Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 7
Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010 10
Table 4: Type 2 Diabetes, World, Major Marketed Drugs, 2010 11
Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III 12
Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030 13
Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005 14
Table 8: Diabetes Drugs Evolution 17
Table 9: Efficacy Results of Galvus in Placebo-controlled Monotherapy Trials 25
Table 10: Efficacy Results of Galvus in Add-on Combination Trials at Week-24 26
Table 11: Approval History of Galvus for Type 2 Diabetes by Indication 27
Table 12: Drug Risk Benefit Score of Galvus 28
Table 13: Annual Cost of Galvus for Type 2 Diabetes, 2010 30
Table 14: Galvus, Type 2 Diabetes, Global, Sales Estimates ($m), 20072020 31
Table 15: Galvus, Type 2 Diabetes, The UK, Sales Estimates ($m), 20072020 32
Table 16: Galvus, Type 2 Diabetes, France, Sales Estimates ($m), 20072020 33
Table 17: Galvus, Type 2 Diabetes, Germany, Sales Estimates ($m), 20072020 34
Table 18: Galvus, Type 2 Diabetes, Italy, Sales Estimates ($m), 20072020 35
Table 19: Galvus, Type 2 Diabetes, Spain, Sales Estimates ($m), 20072020 36
Table 20: Galvus, Type 2 Diabetes, Japan, Sales Estimates ($m), 20102020 37

List of Chart


Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010 
Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030 
Figure 3: Diabetes, World, Mortality, 2010 
Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 
Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 2010–2020 
Figure 6: Mechanism of Action of Sulfonylureas 
Figure 7: Mechanism of Action of Biguanide, Thiozolidinediones, Alpha-Glucosidase Inhibitors 
Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors 
Figure 9: Mechanism of Action of Thiozolidinediones 
Figure 10: Mechanism of Action of DPP IV Inhibitors 
Figure 11: Type 2 Diabetes, Global, Branded Market Share by Value, By Class (%), 2010 
Figure 12: Mechanism of Action of Galvus 
Figure 13: Galvus, Type 2 Diabetes, Global, Sales Estimates ($m), 2007–2020 
Figure 14: Galvus, Type 2 Diabetes, The UK, Sales Estimates ($m), 2007–2020 
Figure 15: Galvus, Type 2 Diabetes, France, Sales Estimates ($m), 2007–2020 
Figure 16: Galvus, Type 2 Diabetes, Germany, Sales Estimates ($m), 2007–2020 
Figure 17: Galvus, Type 2 Diabetes, Italy, Sales Estimates ($m), 2007–2020 
Figure 18: Galvus, Type 2 Diabetes, Spain, Sales Estimates ($m), 2007–2020 
Figure 19: Galvus, Type 2 Diabetes, Japan, Sales Forecasts ($m), 2010–2020 
Figure 20: Galvus, Type 2 Diabetes, Sales Distribution by Country(%), 2020 
Figure 21: Patients Approved for the Drug 

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *